CJC-1295 + Ipamorelin monograph

CJC-1295 + Ipamorelin Monograph

^[1]

This page preserves the structured raw monograph for TroponinIQ Base under the shared content policy. The content is factual reference material; it is not a production prompt or constant update. No Production target: directive was present in the source.

Curation Summary

• Class: Investigational growth hormone secretagogue peptide combination
• Legal/regulatory status: FDA: not approved for bodybuilding/performance enhancement; no labeled FDA-approved product for the CJC-1295 + ipamorelin combination was identified here. Controlled status: not established in the retrieved sources as a DEA controlled substance, but that does not make it legal to market as a drug. WADA: growth hormone secretagogues are prohibited in sport; the WADA Prohibited List page confirms the list prohibits substances/methods in sport, and the retrieved sports-medicine review specifically notes widespread antidoping restrictions for CJC-1295 and ipamorelin. Research-chemical caveat: commonly sold as unapproved injectable peptide products; FDA health-fraud guidance warns that unapproved products marketed with disease or health claims can be illegally sold and hazardous (WADA Prohibited List, PubMed, FDA Health Fraud Product Database).
• Routing: module 03 knowledge for mechanism, clinical/performance context, legal status, safety, and FAQ retrieval.
• Source hash: 73d43935c17ec4b2bd5046b5dcabc54c4c7adb4d2c96704fce589f4620e81a7a

Overview Extract

CJC-1295 and ipamorelin are both research peptides used together in bodybuilding circles to stimulate pulsatile growth hormone release, usually with the goal of better recovery, sleep, or body-composition changes. The combination is not an FDA-approved medicine for bodybuilding, and the human evidence for performance use is thin and largely investigational. Sports-medicine review literature describes growth hormone axis secretagogues such as CJC-1295 and ipamorelin as experimental, with uncertain safety, product-quality concerns, and antidoping restrictions (PubMed).

Use-Case Anchors

• Primary goals: Bodybuilding communities use it for perceived improvements in recovery, sleep quality, lean-mass accrual, connective-tissue support, and fat-loss assistance via GH/IGF-1 elevation. Clinically, these goals are not established indications for the combination, and the best-supported use of GH-axis drugs remains narrow approved endocrine or metabolic indications for other agents, not this blend (PubMed).

Safety / Legal Anchors

• Common side effects: Reported/expected common effects include flushing, transient tingling, headache, dizziness, increased hunger, water retention/bloating, injection-site irritation, and possible sleep-related changes. Community users also report a brief warm-flush sensation after injection, which is consistent with GH secretagogue effects but not specific proof of product quality or effective dosing (Reddit).

FAQ Anchors

• Q: Does CJC-1295 + ipamorelin build muscle?

Source Text

CJC-1295 + Ipamorelin

Overview

CJC-1295 and ipamorelin are both research peptides used together in bodybuilding circles to stimulate pulsatile growth hormone release, usually with the goal of better recovery, sleep, or body-composition changes. The combination is not an FDA-approved medicine for bodybuilding, and the human evidence for performance use is thin and largely investigational. Sports-medicine review literature describes growth hormone axis secretagogues such as CJC-1295 and ipamorelin as experimental, with uncertain safety, product-quality concerns, and antidoping restrictions (PubMed).

Pharmacokinetics & Mechanism

• Class: Investigational growth hormone secretagogue peptide combination
• Mechanism of action: CJC-1295 is a growth hormone-releasing hormone receptor agonist/analogue that stimulates endogenous GH secretion from the pituitary; the DAC (drug affinity complex) version is long-acting because of albumin binding, while the non-DAC/“no DAC” version is short-acting. Ipamorelin is a selective growth hormone secretagogue receptor (GHSR-1a) agonist that promotes pulsatile GH release with relatively minimal cortisol/prolactin signal compared with older secretagogues. Used together, they aim to amplify endogenous GH pulses rather than replace GH directly; however, performance-oriented use is not well supported by robust human outcomes data (PubMed).
• Target(s): Primary targets: GHRH receptor for CJC-1295; ghrelin/growth hormone secretagogue receptor 1a (GHSR-1a) for ipamorelin. Downstream pathway: pituitary somatotroph activation with increased GH secretion and secondary IGF-1 signaling via the GH/IGF-1 axis (NCBI Gene GH1, PubMed).
• Route(s) of administration: Subcutaneous injection is the standard route described in bodybuilding/community use and in peptide research discussions. Not well established for oral or intranasal use; those routes are not standard for these compounds (PubMed).
• Onset: Acute GH pulse effects are expected within about 15-60 minutes after subcutaneous administration based on the intended physiology of GH secretagogues, but precise human onset data for the CJC-1295 + ipamorelin combination are not well established. Community use commonly times injections before bed or away from meals to align with endogenous GH pulses; that timing is anecdotal rather than proven clinical protocol (Reddit, Reddit).
• Half-life: CJC-1295 depends on the variant: the DAC version is long-acting, with published pharmacokinetic descriptions commonly summarized as roughly 5-8 days or a terminal half-life measured in days; the non-DAC version is short-acting and is often described in community discussion as lasting only a short time, but a precise human half-life for the no-DAC version is not well established in the sources retrieved. Ipamorelin is generally described as short-acting with a brief plasma half-life in the minutes range, but the exact human half-life varies across secondary sources and is not consistently established in open authoritative monographs available here. Because of source conflict and limited accessible primary data, treat both as short-to-very-short acting for pulse-stimulation purposes, except CJC-1295 DAC which is extended-duration (PubMed).
• Metabolism / clearance: Not well established in humans for the combination. CJC-1295 DAC is designed for prolonged exposure via albumin binding and eventual proteolytic peptide breakdown; ipamorelin, as a peptide, is expected to undergo enzymatic proteolysis and nonspecific peptide clearance. No authoritative human metabolism/clearance monograph specific to the combination was found in the retrieved sources.

Use-Cases & Dosing Strategies

• Primary goals: Bodybuilding communities use it for perceived improvements in recovery, sleep quality, lean-mass accrual, connective-tissue support, and fat-loss assistance via GH/IGF-1 elevation. Clinically, these goals are not established indications for the combination, and the best-supported use of GH-axis drugs remains narrow approved endocrine or metabolic indications for other agents, not this blend (PubMed).
• Typical protocols: Clinical: no approved labeled clinical dosing protocol exists for the CJC-1295 + ipamorelin combination for bodybuilding or performance enhancement. Research/community anecdotal: common forum patterns include subcutaneous injections once daily, often 100-300 mcg total of each peptide or blended vials used as 200-300 mcg total before bed, frequently 5 days on/2 days off and sometimes twice daily; these are anecdotal reports only and should not be treated as evidence-based dosing (Reddit, Reddit, Reddit).
• Cycle length: Not well established clinically. Community use often runs 4-12 weeks or is used continuously in on/off blocks such as 5 days on and 2 days off, but this is anecdotal and not validated by trials. Because long-term safety is uncertain, prolonged continuous use is hard to justify on a risk-benefit basis (Reddit, PubMed).
• Common stacks: Frequently stacked with other bodybuilding peptides or hormones in community settings, especially growth-hormone-oriented compounds; exact combos vary and are not clinically established. Common anecdotal stacks include the CJC-1295 + ipamorelin blend itself paired with fasting windows, sleep optimization, BPC-157, or exogenous GH-related regimens, but these combinations are not supported as safe or effective medical protocols in the sources retrieved (PubMed).
• Reconstitution / handling (peptides): As peptide lyophilized powders, both are typically reconstituted with bacteriostatic water in community practice and stored refrigerated after mixing. Exact stability, beyond-use dating, and sterility are product- and supplier-dependent and are not well established from authoritative monographs for gray-market materials; contamination and mislabeling are real concerns for unregulated peptide products (PubMed).
• Notes: Food timing is a common community emphasis: users often inject on an empty stomach and avoid food for a period before and after dosing to reduce insulin-related blunting of GH pulses, but that is practice-based rather than proven dosing science. Morning and pre-bed injections are both reported; pre-bed is favored because endogenous GH secretion is higher during sleep. For CJC-1295 DAC, dosing is less frequent because of its long duration; for no-DAC versions, frequent dosing is often discussed, but precise evidence-based timing is lacking (Reddit, Reddit).

Clinical vs. community/anecdotal labeling is noted inline above. Community dosing is not established fact.

Side Effects & Safety / Legal

• Common side effects: Reported/expected common effects include flushing, transient tingling, headache, dizziness, increased hunger, water retention/bloating, injection-site irritation, and possible sleep-related changes. Community users also report a brief warm-flush sensation after injection, which is consistent with GH secretagogue effects but not specific proof of product quality or effective dosing (Reddit).
• Serious / less common: Potential serious or less common risks include edema, numbness/carpal-tunnel-like symptoms, insulin resistance or worsened glucose control, excessive IGF-1 exposure, theoretical concern for tumor promotion in susceptible patients, pituitary-axis disturbance, allergic reaction, and infection or abscess from nonsterile injection. Because these products are often gray-market or compounded outside approved pathways, product contamination, dose inaccuracy, and unknown impurities are major safety hazards (PubMed, FDA Health Fraud Product Database).
• Contraindications: Avoid or use extreme caution in active malignancy, untreated proliferative retinopathy, uncontrolled diabetes or marked insulin resistance, pregnancy/breastfeeding, and any situation where GH/IGF-1 stimulation is undesirable. Caution with other agents that affect glucose or pituitary axes; do not combine casually with exogenous GH/IGF-1 or insulin without medical supervision. Athletes subject to drug testing should treat this as prohibited risk territory (PubMed, WADA Prohibited List).
• Monitoring: If used despite the risks, monitoring should include fasting glucose, HbA1c, IGF-1, blood pressure, body weight/edema, resting heart rate, and symptom review for paresthesia/carpal-tunnel-like complaints. In higher-risk users, consider lipids, liver/kidney function, and cancer surveillance appropriate to history; monitor injection sites for infection. Any unexpected elevation in IGF-1 or worsening glucose control should prompt reassessment.
• Legal / regulatory status: FDA: not approved for bodybuilding/performance enhancement; no labeled FDA-approved product for the CJC-1295 + ipamorelin combination was identified here. Controlled status: not established in the retrieved sources as a DEA controlled substance, but that does not make it legal to market as a drug. WADA: growth hormone secretagogues are prohibited in sport; the WADA Prohibited List page confirms the list prohibits substances/methods in sport, and the retrieved sports-medicine review specifically notes widespread antidoping restrictions for CJC-1295 and ipamorelin. Research-chemical caveat: commonly sold as unapproved injectable peptide products; FDA health-fraud guidance warns that unapproved products marketed with disease or health claims can be illegally sold and hazardous (WADA Prohibited List, PubMed, FDA Health Fraud Product Database).

Chatbot FAQ

Q: Does CJC-1295 + ipamorelin build muscle? A: Maybe indirectly, but not in a way that is well proven in humans for bodybuilding. The physiology makes sense, but the performance data are thin and the practical results are often overstated.

Q: Is the no-DAC version better than CJC-1295 DAC? A: Not automatically. No-DAC is shorter acting and usually dosed more often; DAC lasts much longer. Which one is 'better' depends on the goal, but neither has solid bodybuilding-grade evidence.

Q: When do people usually inject it? A: Most community users inject at night or away from meals, usually on an empty stomach. That is a common practice pattern, not a validated clinical protocol.

Q: What side effect shows it is working? A: A brief flush or warmth is often reported, but that is not proof of an effective dose or a real product. It can happen even when the result you want is not there.

Q: Is it safe to run long term? A: We do not have good human safety data for long-term performance use. If IGF-1 stays elevated or glucose control worsens, the risk-benefit gets worse fast.

Q: Can I stack it with GH or insulin? A: That is not a casual combo. You are layering on more endocrine risk, especially glucose problems and edema, and it should not be done without medical supervision.

Sources

• Injectable Peptides in Sports Medicine: A Structured Review — CJC-1295 and ipamorelin are investigational growth hormone axis secretagogues with uncertain safety, product quality concerns, and antidoping restrictions.
• The Prohibited List — WADA prohibits listed substances and methods in sport; supports anti-doping relevance for peptide secretagogues.
• Health Fraud Product Database — FDA warns about unapproved products marketed with health claims and notes these products may be hazardous and illegally sold.
• GH1 growth hormone 1 [Homo sapiens] — Growth hormone biology and the GH/IGF-1 axis background target pathway.
• CJC-1295 + IPA (no DAC) — no effects yet… dosing too low? — Community anecdotal dosing patterns: 200-300 mcg total, bedtime use, empty-stomach timing, 5-day-on/2-day-off discussion.
• CJC1295 NO DAC IPA and working overnight? — Community anecdotal timing: injections before sleep, empty stomach, claimed short duration for no-DAC version.
• CJC-1295 (NO DAC) 5mg + Ipamorelin 5mg Dosage Guide — Additional anecdotal community dosing discussion; not clinical evidence.

---

Data quality: Thin to mostly anecdotal for performance use. Human sports-medicine review literature labels CJC-1295 and ipamorelin as investigational with uncertain safety and antidoping restrictions; precise half-life and dosing for the combination are not well established in accessible primary human sources. Community dosing reports exist but conflict and should be treated as anecdotal only (PubMed, Reddit, Reddit).